The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial

Pyoderma gangrenosum is a severe ulcerative disease with a great need for novel therapies. A major barrier to the development of novel therapies is a lack of understanding of disease pathogenesis. We present the results of a proof-of-concept open-label clinical trial of IL-23p19 antagonism with tild...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of investigative dermatology 2024-11
Hauptverfasser:	Flora, Akshay, Pham, James, Woods, Jane A., Radzeika, Michael, Dickson, Hugh, Malone, Mathew, Frew, John W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biologics IL-23 Inflammation Pyoderma gangrenosum Wound healing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!